In Market Access for Orphan Drugs: assessing the global landscape, FirstWord goes around the world to lay bare the market access issues affecting orphan drug developers in the US, Asia and Europe. Based on thorough research and European national drug policies translated specifically for FirstWord, the report reviews the challenges, offers insight into strategies being used and includes invaluable comparative tables. Filled with information on trends, patient access schemes and the role of patient organisations, the report is a must-read for orphan drug developers and manufacturers. (Source: FirstWord, December 2013).
You are here: / / Market Access For Orphan Drugs: Assessing The Global Landscape